VectorBuilder and Sartorius have entered into a strategic cooperation agreement aimed at advancing innovation in the biopharmaceutical industry.

GUANGZHOU, China, Nov. 26, 2024 /VB/ — VectorBuilder, a global leader in end-to-end gene delivery services, and Sartorius, a leading international partner in life science research and the biopharmaceutical industry, have recently announced a strategic cooperation agreement. This collaboration will focus on gene vector and mRNA bioprocess solutions and services, aimed at accelerating the development and clinical translation of innovative biopharmaceutical projects.

Expanding on their successful collaboration, Sartorius and VectorBuilder have agreed to broaden the scope of their partnership. The new cooperation will involve various areas, including the co-development of innovative downstream processes for cell and gene therapies, further optimization of the development platform and commercial production of GMP-compliant mRNA, plasmid, and viral vectors, partnering to support sustainability goals, and regular exchange and training of talent from both companies. Additionally, VectorBuilder will serve as a developing partner for applications in the field of new modalities.

Sarah Wang, Head of Sartorius China, stated, “Sartorius is dedicated to customer-centric innovation, which drives our product development and service provision. We believe that this strategic partnership will result in innovative solutions that enhance the efficiency and quality of biomedical enterprises. Together, we aim to support the growth of our global customers and the broader biomedical industry, contributing to the advancement of life sciences through transformative processes.”

Dr. Bruce Lahn, Founder and Chief Scientist of VectorBuilder, expressed, “Innovation is at the core of VectorBuilder. This agreement with Sartorius allows us to expand our impact, providing researchers and pharmaceutical companies worldwide with advanced gene delivery solutions. We are excited to combine our expertise to create a more efficient and effective biopharmaceutical ecosystem.”

Michaela Pischke, Head of the Business Area Separation Technologies, added, “By partnering with VectorBuilder, we aim to leverage the expertise of both companies to drive innovations in downstream processing, reducing time to market and ultimately saving more lives. Congratulations to our China team for their efforts in strengthening this partnership.”

Both companies are committed to exploring the potential of cell and gene therapies and accelerating the translation of research breakthroughs into life-saving treatments.

For more information about Sartorius, visit www.sartorius.com. Learn more about VectorBuilder at www.vectorbuilder.com.

Source: Sartorius